Loading monthly trade data…
Showing all published months. Partner preview tables include up to 20 countries.
USD value by month, all available partner countries combined
Free partner preview shows up to 20 countries.
Total value across the selected data period
| Partner | Value | Share |
|---|---|---|
| United States | $4.3B | 23.1% |
| Australia | $1.4B | 7.6% |
| Hong Kong | $1.4B | 7.3% |
| South Korea | $1.1B | 5.6% |
| United Kingdom | $813.2M | 4.3% |
| Malaysia | $625.3M | 3.3% |
| Poland | $608.9M | 3.2% |
| Philippines | $578.4M | 3.1% |
| France | $556.6M | 3.0% |
| Netherlands | $468.7M | 2.5% |
| Italy | $424.7M | 2.3% |
| Nigeria | $394M | 2.1% |
| Thailand | $352.5M | 1.9% |
| Brazil | $275.4M | 1.5% |
| Singapore | $275.1M | 1.5% |
| Macao | $250.9M | 1.3% |
| Germany | $247.5M | 1.3% |
| Belgium | $236.2M | 1.3% |
| Indonesia | $227.5M | 1.2% |
| Slovenia | $220.3M | 1.2% |
Availability is confirmed when the API response loads.
| Partner | Value | Share |
|---|---|---|
| United States | $83.3M | 24.9% |
| Australia | $22.1M | 6.6% |
| South Korea | $17.8M | 5.3% |
| Belgium | $16.7M | 5.0% |
| Hong Kong | $16.1M | 4.8% |
| Malaysia | $13.8M | 4.1% |
| United Kingdom | $11.2M | 3.4% |
| Philippines | $10.4M | 3.1% |
| Netherlands | $8.7M | 2.6% |
| Poland | $8.7M | 2.6% |
| Macao | $7.8M | 2.3% |
| Slovenia | $6.4M | 1.9% |
| France | $5.4M | 1.6% |
| New Zealand | $5.1M | 1.5% |
| Germany | $4.3M | 1.3% |
| Brazil | $4.3M | 1.3% |
| Singapore | $4.2M | 1.2% |
| India | $4M | 1.2% |
| Peru | $3.7M | 1.1% |
| Italy | $3.6M | 1.1% |
| Year | Export value |
|---|---|
| 2021 | $3.3B |
| 2022 | $3.4B |
| 2023 | $3.2B |
| 2024 | $3.3B |
| 2025 | $3.5B |
| 2026 | $2.1B |
China customs reports HS 300490 at the 8-digit level. 9 subheadings are published under it, and export values for each are available on request.
Sulfonamide-based pharmaceutical preparations formulated into retail packages or measured doses for therapeutic or prophylactic application.
Therapeutic or prophylactic preparations utilizing biphenyl dicarboxylate as the active ingredient, supplied in retail packings or measured doses.
Traditional Chinese medicinal liquors and wines prepared with herbal ingredients, packaged for retail sale or dispensed in measured therapeutic doses.
The specific traditional Chinese compound formula known as Pien Tze Huang, packaged for retail sale or provided in measured doses.
The traditional Chinese herbal formulation recognized as Bai Yao, prepared for retail sale or dispensed in individually measured doses.
Topical essential balm formulated for therapeutic use, packaged for retail sale or contained in measured doses for prophylactic application.
Retail-packaged or dose-measured Angong niuhuang wan, a specific traditional Chinese medicinal formulation used for therapeutic or prophylactic purposes.
Traditional Chinese medicinal preparations for retail sale or measured dosing, excluding the specifically classified Angong niuhuang wan formulation.
Pharmaceutical preparations for therapeutic or prophylactic retail sale that do not fall under Chinese-type medicines or other specifically named categories.
Public data shows up to 20 partner countries. Request all available countries, years, quantity fields, or HS8 detail in CSV or Excel.
HS 300490 is also written 3004.90. Values are in USD; the public series does not report tonnes or kg. Product scope: Retail-packaged pharmaceutical drugs and medicines intended for treatment or disease prevention, capturing formulations not specifically classified elsewhere such as antibiotics, vitamins, or hormones. The public page shows monthly export partner previews from official GACC customs statistics. Full partner-month rows are available through a scoped custom data request.
Source: China General Administration of Customs (GACC), cleaned and structured by China Data Portal.
Transformations: Values are presented as published by the source.
China Data Portal. "China Medicaments (HS 300490) Export Data." https://chinadata.live/china-trade/hs/300490/
HS 300490 is also written 3004.90. Values are in USD; the public series does not report tonnes or kg. Product scope: Retail-packaged pharmaceutical drugs and medicines intended for treatment or disease prevention, capturing formulations not specifically classified elsewhere such as antibiotics, vitamins, or hormones. The public page shows monthly export partner previews from official GACC customs statistics. Full partner-month rows are available through a scoped custom data request.
Source: China General Administration of Customs (GACC), cleaned and structured by China Data Portal.
Transformations: Values are presented as published by the source.
China Data Portal. "China Medicaments (HS 300490) Export Data." https://chinadata.live/china-trade/hs/300490/
China exported $3.6B of medicaments in the twelve months to July 2026, averaging $301M per month, based on official China customs statistics (HS 300490).
Retail-packaged pharmaceutical drugs and medicines intended for treatment or disease prevention, capturing formulations not specifically classified elsewhere such as antibiotics, vitamins, or hormones.
United States, Australia and Hong Kong together account for 38% of the published total, out of 152 trading partners on record.
Annual exports grew by 8% between 2021 and 2025, from $3.3B to $3.5B.
Figures come from official China General Administration of Customs (GACC) statistics, published monthly. ChinaData cleans partner names, periods and values so the series is ready for analysis. Partner-level rows for every month, including HS8 detail, are available on request.